Researcher
Christophe Deroose
- Disciplines:Medical imaging and therapy, Medicinal products
Affiliations
- Nuclear Medicine & Molecular Imaging (Division)
Member
From1 Oct 2002 → Today
Projects
1 - 10 of 30
- Development and preclinical evaluation of diagnostic and therapeutic radiopharmaceuticals for pancreatic cancerFrom2 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Multicenter validation trial of [18F]AlF-FAPI-74 for PET imaging of cancer-associated fibroblasts through fibroblast activation protein inhibitors (FAPI) in digestive tumorsFrom1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- '213Bi-188Ready' Improved Theranostics with Bismuth-213 and Rhenium-188From1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- [18F]AlF-NOTA-octreotide PET imaging of the somatostatin receptor in neuroendocrine tumors: comparison with [68Ga]Ga-DOTATATE and evaluation of routine clinical use.From3 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Targeted alpha therapy of pancreatic tumors in a theranostic settingFrom1 Oct 2022 → TodayFunding: BOF - projects, Fund Recuperation Fiscal Exemption
- IMAGINATION : IMAGing bIomarkers for diagNosis, therAnosTIcs and drug develOpmeNtFrom1 Oct 2022 → TodayFunding: IOF - mandates
- Development and preclinical evaluation of diagnostic and therapeutic radiopharmaceuticals targeting CXCR4From10 Aug 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- 18F-PSMA-1007 PET/MR imaging, quantification and radiomics in the primary staging of prostate cancer and response prediction after neoadjuvant hormonal therapyFrom1 Aug 2021 → TodayFunding: FWO Strategic Basic Research Grant
- New Strategies in Locoregional, Minimally Invasive Therapy of Liver CancerFrom1 Jul 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Positron emission tomography combined with innovative laboratory techniques for improved risk and disease assessment in myeloma.From1 Jan 2021 → TodayFunding: FWO Applied Biomedical Research (TBM)
Publications
1 - 10 of 221
- The LUTIA trial: a small step for PRRT, a giant leap for intra-arterial radionuclide therapy trial methodology(2024)
Authors: Christophe Deroose
Pages: 1133 - 1135 - Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside(2024)
Authors: Christophe Deroose, Kristof Baete, Thomas Elias Cocolios, Frederik Cleeren
Pages: 1720 - 1743 - PSMA PET/CT and PET/MRI in primary staging of prostate cancer and its effect on patient management(2024)
Authors: Alexander Giesen, Steven Joniau, Koen Van Laere, Michel Koole, Christophe Deroose, Karolien Goffin
Pages: 31 - 54 - Use and perceived utility of [18F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022(2024)
Authors: Christophe Deroose
- Targeted STAT1 therapy for LZTR1-driven peripheral nerve sheath tumor(2023)
Authors: Christopher Cawthorne, Willy Gsell, Greetje Vande Velde, Christophe Deroose, Koen Van Laere, Uwe Himmelreich, Raj Sewduth, Anna Sablina
Pages: 1386 - 1390 - How to attract young talent to nuclear medicine step 1: a survey conducted by the EANM Oncology and Theranostics Committee to understand the expectations of the next generation(2023)
Authors: Christophe Deroose, Karolien Goffin
Pages: 3 - 11 - Joint EANM/SNMMI/IHPBA procedure guideline for [99mTc]Tc-mebrofenin hepatobiliary scintigraphy SPECT/CT in the quantitative assessment of the future liver remnant function(2023)
Authors: Christophe Deroose
Pages: 1131 - 1144 - Not all black colons on [18F]FDG PET are due to metformin(2023)
Authors: Vibeke Vergote, Daan Dierickx, Thomas Tousseyn, Didier Bielen, Koen Van Laere, Christophe Deroose, Karolien Goffin
Pages: 3477 - 3478 - Impact on clinical management when using [18F]AlFNOTA-octreotide instead of [68Ga]Ga-DOTA-SSA PET/CT in neuroendocrine tumor patients: preliminary results(2023)
Authors: Jeroen Dekervel, Frederik Cleeren, Michel Koole, Guy Bormans, Chris Verslype, Christophe Deroose
Pages: S508 - S508 - Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups(2023)
Authors: Christophe Deroose, Ann Smeets
Pages: E331 - E343